Julie Mariotti
Family Medicine · Royal Oak, MINPI 1790767374
Payments from drug & device makers
Across 148 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$393
- AbbVie$255
- Novo Nordisk$251
- Pfizer$230
- Boehringer Ingelheim$181
- Lilly USA, LLC$139
- plus $944 from 20 others
What the payments were for
- Food & beverage$2,393100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $393 |
| AbbVie(2 entities) | 16 | $255 |
| Novo Nordisk | 17 | $251 |
| Pfizer | 15 | $230 |
| Boehringer Ingelheim | 10 | $181 |
| Lilly USA, LLC | 10 | $139 |
| Astellas Pharma US Inc | 8 | $138 |
| Amgen | 6 | $110 |
| Amarin Pharma, Inc. | 6 | $108 |
| GSK | 3 | $67 |
| Ironshore Pharmaceuticals Inc. | 4 | $65 |
| Johnson & Johnson | 4 | $63 |
| Exact Sciences | 3 | $50 |
| Merck | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Bayer | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Novartis | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Bioventus LLC | 1 | $14 |
How this compares
$2,393 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 12 | $16,575 |
| EliquisApixaban | 11 | $15,992 |
| JardianceEmpagliflozin | 17 | $14,381 |
| Atorvastatin Calcium | 128 | $1,839 |
| Omeprazole | 62 | $1,171 |
| Levothyroxine Sodium | 96 | $1,055 |
| Losartan Potassium | 74 | $957 |
| Metoprolol Succinate | 47 | $934 |
| Metformin Hcl | 64 | $848 |
| Rosuvastatin Calcium | 38 | $779 |
| Celecoxib | 15 | $709 |
| Pravastatin Sodium | 29 | $634 |
| Lisinopril | 77 | $611 |
| Duloxetine Hcl | 17 | $596 |
| Amlodipine Besylate | 73 | $549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $393 | $16,57512 claims |
| PfizerEliquis | $230 | $15,99211 claims |
| Boehringer IngelheimJardiance | $181 | $14,38117 claims |
| AbbVieSynthroid | $255 | $38912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Royal Oak
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.